Daraxonrasib Doubles Survival in Pancreatic Cancer — But Experts Urge Caution

References

1. 1.Califano, A., & Bosker, G. (2026). The real work for making dramatic gains against pancreatic cancer is just beginning. STAT News. https://www.statnews.com/2026/06/19/daraxonrasib-pancreatic-cancer-miracle-drug-oncosystems-ai/
2. 2.U.S. Food and Drug Administration. (2026). FDA early access designation for daraxonrasib in pancreatic cancer. FDA Announcements. https://www.fda.gov
3. 3.Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12–49. https://doi.org/10.3322/caac.21820
4. 4.Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023). Pancreatic cancer: Advances and challenges. Cell, 186(8), 1729–1754. https://doi.org/10.1016/j.cell.2023.02.014
5. 5.Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021). Estimated projection of US cancer incidence and death to 2040. JAMA Network Open, 4(4), e214708. https://doi.org/10.1001/jamanetworkopen.2021.4708
6. 6.Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., & Ducreux, M. (2023). Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial. JAMA Oncology, 9(2), 173–180. https://doi.org/10.1001/jamaoncol.2022.7243
7. 7.Cancer Australia. (2023). Pancreatic cancer in Australia: Statistics and data. Cancer Australia. https://www.canceraustralia.gov.au/cancer-types/pancreatic-cancer/statistics
8. 8.Califano, A., & Alvarez, M. J. (2017). The recurrent architecture of tumour initiation, progression and drug sensitivity. Nature Reviews Cancer, 17(2), 116–130. https://doi.org/10.1038/nrc.2016.124